Free Trial
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Price, News & Analysis

Cocrystal Pharma logo
$1.42 -0.05 (-3.72%)
As of 03/31/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cocrystal Pharma Stock (NASDAQ:COCP)

Key Stats

Today's Range
$1.38
$1.46
50-Day Range
$1.42
$2.28
52-Week Range
$1.35
$3.26
Volume
19,608 shs
Average Volume
29,098 shs
Market Capitalization
$14.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Remove Ads

Cocrystal Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

COCP MarketRank™: 

Cocrystal Pharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 374th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cocrystal Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Cocrystal Pharma are expected to decrease in the coming year, from ($1.85) to ($2.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cocrystal Pharma is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cocrystal Pharma is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cocrystal Pharma has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cocrystal Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.02% of the float of Cocrystal Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cocrystal Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cocrystal Pharma has recently decreased by 90.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cocrystal Pharma does not currently pay a dividend.

  • Dividend Growth

    Cocrystal Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Cocrystal Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cocrystal Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cocrystal Pharma has recently decreased by 90.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cocrystal Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.64% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 6.72% of the stock of Cocrystal Pharma is held by institutions.

  • Read more about Cocrystal Pharma's insider trading history.
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

COCP Stock News Headlines

New “Trump” currency proposed in DC
After a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out first. Warren Buffett sold off 115 million shares of Apple last year.
Cocrystal Pharma, Inc. (COCP)
COCP: Phase 2a Trial of CC-42344 Extended…
See More Headlines

COCP Stock Analysis - Frequently Asked Questions

Cocrystal Pharma's stock was trading at $2.02 at the start of the year. Since then, COCP stock has decreased by 29.7% and is now trading at $1.42.
View the best growth stocks for 2025 here
.

Cocrystal Pharma, Inc. (NASDAQ:COCP) announced its earnings results on Thursday, March, 27th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.23.

Shares of Cocrystal Pharma reverse split before market open on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE).

Company Calendar

Last Earnings
3/27/2025
Today
3/31/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+393.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.59 per share
Price / Book
0.55

Miscellaneous

Free Float
7,565,000
Market Cap
$14.45 million
Optionable
Not Optionable
Beta
2.35
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:COCP) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners